MedTrace Logo

A Phase I Study of Oral UE2343 in Healthy Subjects

NCT01770886 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2013-07-17

No results posted yet for this study

Summary

A randomised, double-blind, placebo-controlled, phase I study in healthy subjects. Safety, pharmacokinetic and pharmacodynamic data will be collected.

Conditions

  • Healthy

Interventions

DRUG

UE2343

Oral capsule

DRUG

Placebo

Oral capsule

Sponsors & Collaborators

  • Wellcome Trust

    collaborator OTHER

  • Simbec Research

    collaborator INDUSTRY

  • University of Edinburgh

    lead OTHER

Principal Investigators

  • Brian R Walker, BSc MBChB MD · University of Edinburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01770886 on ClinicalTrials.gov